2025 United States Anti-Asthmatics And Copd Drugs Market Revenue Opportunities Report
Description
The 2025 United States Anti-Asthmatics And Copd Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthmatics and COPD Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. Anti-Asthmatics and COPD drugs market are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK leads with its extensive respiratory portfolio, including innovative biologics such as depemokimab and acquisitions like Aiolos Bio, enhancing its asthma treatment pipeline. AstraZeneca anchors its market position through a broad inhaler range and biologics, supported by strategic acquisitions like Almirall's respiratory assets. Boehringer Ingelheim and Novartis also remain key players with strong inhaler offerings and advanced respiratory therapies, including biologics and combination drugs.
Together, these companies dominate the U.S. Anti-Asthmatics and COPD market, driven by rising disease prevalence—25 million Americans with asthma and 16 million with COPD—and government initiatives like Healthy People 2030 to improve respiratory health. The market is expanding with a 5-6% CAGR, fueled by innovation in biologics, inhaler technologies, and digital health integrations for therapy monitoring. Online pharmacy growth and advancements in long-acting biologics further support their market leadership.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthmatics and COPD Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. Anti-Asthmatics and COPD drugs market are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK leads with its extensive respiratory portfolio, including innovative biologics such as depemokimab and acquisitions like Aiolos Bio, enhancing its asthma treatment pipeline. AstraZeneca anchors its market position through a broad inhaler range and biologics, supported by strategic acquisitions like Almirall's respiratory assets. Boehringer Ingelheim and Novartis also remain key players with strong inhaler offerings and advanced respiratory therapies, including biologics and combination drugs.
Together, these companies dominate the U.S. Anti-Asthmatics and COPD market, driven by rising disease prevalence—25 million Americans with asthma and 16 million with COPD—and government initiatives like Healthy People 2030 to improve respiratory health. The market is expanding with a 5-6% CAGR, fueled by innovation in biologics, inhaler technologies, and digital health integrations for therapy monitoring. Online pharmacy growth and advancements in long-acting biologics further support their market leadership.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
